News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sigma-Tau Group : A New Efficient and Cost Effective Dialysis for Patients With End Stage Renal Disease



6/18/2013 12:21:31 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ROME--(BUSINESS WIRE)--Thule Therapeutics S.A., an R&D Company of the Sigma-Tau Group, and Corequest Sagl announce extremely valuable findings on the use of L-Carnitine in peritoneal dialysis solutions opening up new opportunities in the treatment of end stage renal disease (ESRD).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES